K
Gene therapy company developing AAV-based therapies for highly prevalent chronic diseases, including geographic atrophy, thyroid eye disease, and type 1 diabetes. Bicoastal since founding, with gene-therapy manufacturing and process development anchored in RTP and a Palo Alto office. Raised $320M Series D in September 2025, one of the largest NC life-sciences rounds of the year.
At a glance
- Founded: 2019
- HQ: Durham
- Sector: Biotech
- Stage: Growth
- Total raised: $770.5M
- Last round: Growth
This is the free preview.
The full profile is for members: founders, funding history, investor connections, and recent signals. Accounts are free; I review every request, usually within 48 hours.